{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:47Z","timestamp":1790758727773,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01006-9","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T19:12:29Z","timestamp":1616699549000},"page":"938-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-6456","authenticated-orcid":false,"given":"Caroline","family":"Ruetsch-Chelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Bresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Desnuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Brglez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ticchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01006-9_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"10.1007\/s13311-021-01006-9_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol."},{"key":"10.1007\/s13311-021-01006-9_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"10.1007\/s13311-021-01006-9_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol."},{"key":"10.1007\/s13311-021-01006-9_bib6","doi-asserted-by":"crossref","unstructured":"Jiang R, Fichtner ML, Hoehn KB, Stathopoulos P, Nowak RJ, Kleinstein SH, et al. Single-cell repertoire tracing identifies rituximab refractory B cells during myasthenia gravis relapses. bioRxiv. Cold Spring Harbor Laboratory; 2020;840389.","DOI":"10.1101\/840389"},{"key":"10.1007\/s13311-021-01006-9_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney International. Elsevier"},{"key":"10.1007\/s13311-021-01006-9_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"10.1007\/s13311-021-01006-9_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jnnp-2018-319410","article-title":"Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab","volume":"90","author":"Chan","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1007\/s13311-021-01006-9_bib11","first-page":"1","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther. BioMed Central"},{"key":"10.1007\/s13311-021-01006-9_bib12","doi-asserted-by":"crossref","unstructured":"Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, et al. Use and monitoring of low dose rituximab in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry. British Medical Association; 2011;659.","DOI":"10.1136\/jnnp.2010.220475"},{"key":"10.1007\/s13311-021-01006-9_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.5607\/en.2019.28.6.720","article-title":"B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis","volume":"28","author":"Min","year":"2019","journal-title":"Exp Neurobiol."},{"key":"10.1007\/s13311-021-01006-9_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib17","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mt Sinai J Med."},{"key":"10.1007\/s13311-021-01006-9_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring Clinical Treatment Response in Myasthenia Gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin."},{"key":"10.1007\/s13311-021-01006-9_bib19","doi-asserted-by":"crossref","unstructured":"Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology. 2000;","DOI":"10.1007\/s004150050585"},{"key":"10.1007\/s13311-021-01006-9_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J Neuroimmunol."},{"key":"10.1007\/s13311-021-01006-9_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mus.26790","article-title":"Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis","volume":"61","author":"Lu","year":"2020","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-021-01006-9_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-021-01006-9_bib24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.nmd.2017.06.012","article-title":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","volume":"27","author":"Muto","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"10.1007\/s13311-021-01006-9_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419871187","article-title":"Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis","volume":"12","author":"Choi","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1007\/s13311-021-01006-9_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B cell depletion therapy in MS according to memory B cell monitoring","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1007\/s13311-021-01006-9_bib27","doi-asserted-by":"crossref","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O'Connor KC. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight. 2017;2.","DOI":"10.1172\/jci.insight.94263"},{"key":"10.1007\/s13311-021-01006-9_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1007\/s13311-021-01006-9_bib29","first-page":"347","article-title":"Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis","volume":"33","author":"Roll","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"10.1007\/s13311-021-01006-9_bib30","doi-asserted-by":"crossref","first-page":"102175","DOI":"10.1016\/j.msard.2020.102175","article-title":"Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules","volume":"43","author":"Trewin","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders."},{"key":"10.1007\/s13311-021-01006-9_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01006-9_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182927","article-title":"B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis","volume":"12","author":"Moura","year":"2017","journal-title":"PLoS ONE."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01006-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:46Z","timestamp":1761807106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011418"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01006-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01006-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}